安徽华人健康医药股份有限公司 内幕信息知情人登记管理制度 第一章 总则 董事会秘书具体负责公司内幕信息的日常管理工作，证券部是公司信息 披露管理、投资者关系管理、内幕信息登记备案的日常办事机构。 公司审计委员会对内幕信息知情人登记管理制度实施情况进行监督。 第二章 内幕信息及内幕信息知情人的范围 第六条 本制度所指内幕信息是指根据《证券法》相关规定，涉及公司的经营、 财务或者对公司股票、证券及其衍生品种交易价格有重大影响的尚未公 开的信息。包括但不限于： （一）公司的经营方针和经营范围的重大变化； （二）公司的重大投资行为，公司在一年内购买、出售重大资产超过公 司资产总额百分之三十，或者公司营业用主要资产的抵押、质押、出售 或者报废一次超过该资产的百分之三十； （三）公司订立重要合同、提供重大担保或者从事关联交易，可能对公 司的资产、负债、权益和经营成果产生重要影响； （四）公司发生重大债务和未能清偿到期债务的违约情况； （五）公司发生重大亏损或者重大损失； （六）公司生产经营的外部条件发生的重大变化； （七）公司的董事、或者总裁发生变动，董事长或者总裁无法履行职责； （八）持有公司百分之五以上股份的股东或者 ...

Core Viewpoint - The pharmaceutical and biotechnology industry is experiencing moderate performance, with the introduction of the commercial insurance innovative drug catalog and the deepening application of artificial intelligence in healthcare presenting structural opportunities for growth [1][3]. Group 1: Commercial Insurance Innovative Drug Catalog - The National Healthcare Security Administration and the National Health Commission have jointly released measures to support the high-quality development of innovative drugs, establishing a commercial insurance innovative drug catalog that focuses on innovative drugs with significant clinical value but outside the scope of medical insurance [1]. - The catalog aims to eliminate barriers for high-value innovative drugs through a "three exclusions" policy, which does not count towards the self-pay rate of medical insurance, monitors alternative products, and limits payment by disease type [1]. - The actual effectiveness of the catalog depends on the payment capabilities of commercial insurance and the collaboration with medical institutions, with the current payment proportion for innovative drugs being less than 8%, while the policy aims to increase this to 44% over the next decade [1][2]. Group 2: AI in Healthcare - Artificial intelligence is rapidly penetrating the entire pharmaceutical industry chain, significantly shortening drug development cycles and reducing costs through target screening, molecular design, and clinical trial optimization [3]. - The National Science and Technology Major Project has allocated 1.75 billion yuan for AI-assisted new drug development projects, focusing on breakthroughs in infectious diseases and rare diseases by 2025 [3]. - The intelligent transformation of medical services is also accelerating, with AI-assisted diagnostic systems becoming more mature in applications such as imaging recognition and pathological analysis [3]. - Despite optimism about the long-term potential of AI technology, challenges such as data fragmentation, privacy protection, and the lack of interpretability of AI models remain significant barriers to large-scale application [3].

Group 1 - The company plans to issue A-shares to specific investors, pending approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission (CSRC) [2][3][4] - The final issuance price will be no less than 85% of the average trading price of the company's shares over the 20 trading days prior to the pricing date [3][4][5] - The total number of shares to be issued will not exceed 25% of the company's total share capital, amounting to a maximum of 83,530,821 shares [5][6] Group 2 - The funds raised will be allocated to specific projects, including the construction of a production base for amino acids and an enhancement project for raw materials [6][7] - The company may adjust the investment priorities and amounts based on the actual net amount raised and project urgency if the net proceeds are less than planned [6][7] - The company has committed to using the raised funds in compliance with relevant regulations and will replace any pre-invested funds once the raised funds are available [6][7] Group 3 - The company operates in the pharmaceutical industry, which is subject to strict regulatory oversight from various government bodies, including the National Medical Products Administration and the National Healthcare Security Administration [19][20] - The pharmaceutical industry is characterized by significant competition and regulatory challenges, including drug approval processes and pricing regulations [19][20][21] - The company’s business encompasses pharmaceutical distribution, manufacturing, and health services, with a focus on both commercial and industrial sectors [19][20]

Group 1 - The company has announced its 2024 annual profit distribution plan, which involves a cash dividend of 3.5 RMB per 10 shares for all shareholders, based on a total share capital of 388,516,736 shares [1][2] - The distribution plan is consistent with the allocation scheme approved by the shareholders' meeting and will be adjusted if the total share capital changes before the implementation [1] - The record date for the distribution is set for July 9, 2025, and the ex-dividend date is July 10, 2025 [1][2] Group 2 - The distribution is applicable to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of the record date [2] - The cash dividends will be directly credited to the shareholders' accounts through their securities companies or other custodians [2] - The company assumes all legal responsibilities for any insufficient cash dividends due to a decrease in shares held by shareholders during the distribution application period [2]

Core Viewpoint - The company has approved the use of up to RMB 2.5 billion of idle self-owned funds for cash management, which includes investments in various financial products to enhance investment efficiency and returns for shareholders [1][2]. Cash Management Overview - The company will utilize idle funds for cash management, including fixed-income or capital-protected floating income financial products, large deposits, and time deposits [1]. - A contract has been signed with Guangfa Bank for a structured deposit linked to gold, with expected annual returns of 1%, 2%, or 2.1% [1][4]. Investment Risk Analysis - The cash management investments are considered low-risk, but they may still be affected by macroeconomic conditions and market fluctuations [2]. - The company will monitor the financial market and adjust its investment strategy accordingly to mitigate risks [2]. Impact on Company - The cash management strategy aims to improve the overall performance of the company and provide better returns to shareholders without affecting the normal operations of the company or its main business activities [2].

Group 1 - Hubei Province's direct financing has maintained a high level of around 800 billion yuan for three consecutive years, with nearly 80% of listed companies achieving profitability [1][2] - As of June 30, 2025, Hubei has 191 listed companies, ranking 10th nationally, with 153 domestic and 38 overseas listings [2][3] - The province has a reserve of 1,355 "gold and silver seed" enterprises to support more quality companies to go public [1][4] Group 2 - In Q1 2025, over 70% of Hubei's listed companies were profitable, with notable companies like Jiuzhoutong, CITIC Special Steel, and Wentai Technology reporting revenues exceeding 10 billion yuan [3] - The top ten companies by revenue in Hubei all exceeded 4 billion yuan, indicating strong performance in the region [3] - Hubei has implemented a comprehensive service system for companies to enter the multi-level capital market, aiming to enhance the quality of enterprises [4] Group 3 - Hubei's capital market reforms have led to 20 new listings and approvals annually from 2021 to 2023, with the province ranking 6th nationally for new listings in 2024 [2] - The province aims to achieve five major goals by 2030, including increasing the total number of listed companies and ensuring coverage across all regions [4]

Core Viewpoint - The announcement details the profit distribution plan for Ruikang Pharmaceutical Group Co., Ltd. for the fiscal year 2024, which has been approved by the shareholders' meeting held on May 16, 2025, and specifies the cash dividend distribution without issuing new shares [1][2]. Summary by Sections Profit Distribution Plan - The total amount for profit distribution is calculated as 5,937,055.82 yuan, based on a distribution ratio of 0.004 yuan per share for 1,484,263,954 shares [1]. - The cash dividend per share after the distribution will be adjusted to 0.0039456 yuan, calculated as the total cash dividend divided by the total share capital [1]. Changes in Share Distribution - If the total number of shares entitled to profit distribution changes due to convertible bonds, share buybacks, stock option exercises, or new shares from refinancing before the implementation of the profit distribution plan, the total dividend amount will be adjusted accordingly based on the number of shares on the record date [2]. Rights and Dates - The record date for the profit distribution is set for July 7, 2025, and the ex-dividend date is July 8, 2025 [2][3]. - The distribution will be directly credited to the shareholders' accounts through their custodial securities companies [3]. Distribution Recipients - The recipients of the profit distribution will be all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of the record date [3]. Consultation Information - For inquiries regarding the profit distribution, shareholders can contact the company's securities affairs department at the provided address and phone number [3][4].

Core Viewpoint - The company, Harbin Pharmaceutical Group People's Tongtai Pharmaceutical Co., Ltd., has provided detailed responses to inquiries regarding its financial disclosures, particularly focusing on customer and supplier relationships, accounts receivable, and cash flow management [1][3][6]. Financial Performance - The company's top five customers generated sales of 1.754 billion yuan, accounting for 17.46% of total annual sales, while the top five suppliers had procurement amounts of 1.742 billion yuan, representing 14.85% of total annual purchases [1]. - The end-of-period accounts receivable from the top five debtors amounted to 1.060 billion yuan, making up 24.92% of total accounts receivable [1]. Customer and Supplier Relationships - Major customers in the medical distribution business include public hospitals, private hospitals, community health service centers, and clinics, while suppliers consist of joint ventures and domestic pharmaceutical companies [1]. - The company has identified 47 overlapping customers and suppliers, primarily in the pharmaceutical commercial sector, indicating a need for mutual procurement to meet market demands [2][3]. Accounts Receivable Management - The company has established a dual management standard for credit limits and terms for all credit sales customers, with varying credit periods based on customer type [3]. - The total accounts receivable as of 2024 was 4.256 billion yuan, with a bad debt provision of 202.1 million yuan [3]. Cash Flow and Financial Health - The ratio of cash received from sales to operating income has remained consistent over the past five years, indicating stable cash flow management [4][6]. - The company has implemented measures to control credit risk and improve accounts receivable collection, including a comprehensive management system and regular customer evaluations [3][4]. Other Payables - As of the end of the reporting period, the company reported other payables of 365 million yuan, with significant amounts related to logistics projects and employee settlement fees [8][9]. - The company has clarified that the majority of its other payables are not related to transactions with related parties, ensuring compliance with disclosure requirements [9].

Core Viewpoint - The actual controllers of Jianzhijia (605266), Mr. Lan Bo and Ms. Shu Chang, have increased their shareholding ratio from 40.6787% to 40.7056% due to the appointment of senior management by three partnership enterprises, resulting in a total increase of 0.0269% in shareholding [1] Summary by Relevant Sections - Shareholding Change - The shareholding ratio of the actual controllers has risen by 0.0269% [1] - The new shareholding ratio stands at 40.7056% [1] - Management and Control - The increase in shareholding is attributed to the alignment of interests between senior management and the partnership enterprises, establishing a concerted action relationship with the actual controllers [1] - This change does not trigger a mandatory tender offer and will not alter the status of the actual controllers or the controlling shareholders [1]

Core Viewpoint - The company, Jiasitang Pharmaceutical Co., Ltd., has revised its Articles of Association to enhance corporate governance and compliance with regulatory requirements [1][2]. Summary by Relevant Sections Corporate Governance - The revision includes the addition of a section on independent directors to clarify their responsibilities and duties [1][2]. - A new chapter on the specialized committees of the board has been introduced to define their roles and responsibilities more clearly [1][2]. Terminology Adjustments - The term "shareholders' meeting" has been changed to "shareholders' assembly" throughout the document [1][2]. Compliance and Regulatory Updates - The revisions align with the Company Law of the People's Republic of China, the Guidelines for Articles of Association of Listed Companies, and the Shenzhen Stock Exchange Listing Rules [1][2]. - Outdated regulatory references have been removed from the Articles [1][2]. Operational Changes - The position of Chief Executive Officer has been removed, and the powers of the President have been refined [1][2]. - New provisions have been added regarding the reporting obligations if a shareholders' assembly cannot be held on time [2]. Future Actions - The proposed amendments will be submitted for approval at the second extraordinary general meeting of shareholders in 2025, after which the company will proceed with the necessary business registration procedures [2].